(AOF) – Lysogene, a biopharmaceutical company based on a gene therapy technology platform targeting diseases of the central nervous system, today announces the appointment of Côme de La Tour du Pin, currently Vice President Finance since 2020 and Chief Financial Officer ad interim since November 2022, as Chief Financial Officer. He will replace Stéphane Durant des Aulnois, Chief Financial Officer since October 2019, who has decided to leave the company to pursue other opportunities.
A graduate of EM Lyon Business School, Côme de La Tour du Pin has been involved in fundraising, investor relations and FP&A activities. Before joining Lysogene, he gained experience in investor relations at Ipsen and at Casino. He had previously developed skills in investment banking at BNP Paribas and in auditing at PwC.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.